Lost in translation: Endoplasmic reticulum stress and the decline of β-cell health in diabetes mellitus

Diabetes, Obesity and Metabolism

Volumn 15, Issue S3, 2013, Pages 159-169

  Evans Molina, C ^a   Hatanaka, M ^a   Mirmira, R G ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Diabetes; ER stress; Islet; MRNA translation; Polyribosome

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 4 PHENYLBUTYRIC ACID; 6 [[2 [[2 (2 CYANO 1 PYRROLIDINYL) 2 OXOETHYL]AMINO]ETHYL]AMINO]NICOTINONITRILE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; IMATINIB; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; LINAGLIPTIN; LIRAGLUTIDE; MK 626; MONOCLONAL ANTIBODY CD3; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; SITAGLIPTIN; SUNITINIB; TAUROURSODEOXYCHOLIC ACID; UNCLASSIFIED DRUG; VILDAGLIPTIN;

ANTIDIABETIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; DIABETES MELLITUS; ENDOPLASMIC RETICULUM STRESS; GASTROINTESTINAL STROMAL TUMOR; HUMAN; IMMUNE RESPONSE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN RESISTANCE; KIDNEY CARCINOMA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; POLYSOME; REVIEW; RNA TRANSLATION; TRANSLATION INITIATION; TRANSLATION REGULATION; UNFOLDED PROTEIN RESPONSE; UREA CYCLE DISORDER;

DIABETES; ER STRESS; ISLET; MRNA TRANSLATION; POLYRIBOSOME;

ANIMALS; DIABETES MELLITUS; ENDOPLASMIC RETICULUM STRESS; HUMANS; INSULIN-SECRETING CELLS; PROTEIN BIOSYNTHESIS; RNA, MESSENGER; UNFOLDED PROTEIN RESPONSE;

EID: 84883529653     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12163     Document Type: Review

References (103)

1. Matsuda T, Kido Y, Asahara S-I et al. Ablation of C/EBPbeta alleviates ER stress and pancreatic beta cell failure through the GRP78 chaperone in mice. J Clin Invest 2010; 120: 115-126.
2. Florez JC. Newly identified loci highlight beta cell dysfunction as a key cause of type 2 diabetes: where are the insulin resistance genes? Diabetologia 2008; 51: 1100-1110.
3. Shen J, Prywes R. Dependence of site-2 protease cleavage of ATF6 on prior site-1 protease digestion is determined by the size of the luminal domain of ATF6. J Biol Chem 2004; 279: 43046-43051.
4. Yamamoto K, Sato T, Matsui T et al. Transcriptional induction of mammalian ER quality control proteins is mediated by single or combined action of ATF6alpha and XBP1. Dev Cell 2007; 13: 365-376.
5. Harding HP, Novoa I, Zhang Y et al. Regulated translation initiation controls stress-induced gene expression in mammalian cells. Mol Cell 2000; 6: 1099-1108.
6. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003; 52: 102-110.
7. Palam LR, Baird TD, Wek RC. Phosphorylation of eIF2 facilitates ribosomal bypass of an inhibitory upstream ORF to enhance CHOP translation. J Biol Chem 2011; 286: 10939-10949.
8. Festa A, Williams K, D'Agostino RJ, Wagenknecht LE, Haffner SM. The natural course of beta-cell function in nondiabetic and diabetic individuals: the Insulin Resistance Atherosclerosis Study. Diabetes 2006; 55: 1114-1120.
9. Gupta S, McGrath B, Cavener DR. PERK (EIF2AK3) regulates proinsulin trafficking and quality control in the secretory pathway. Diabetes 2010; 59: 1937-1947.
10. Mak BC, Wang Q, Laschinger C et al. Novel function of PERK as a mediator of force-induced apoptosis. J Biol Chem 2008; 283: 23462-23472.
11. Song B, Scheuner D, Ron D, Pennathur S, Kaufman RJ. Chop deletion reduces oxidative stress, improves beta cell function, and promotes cell survival in multiple mouse models of diabetes. J Clin Invest 2008; 118: 3378-3389.
12. Ginter E, Simko V. Global prevalence and future of diabetes mellitus. Adv Exp Med Biol 2012; 771: 35-41.
13. Allagnat F, Fukaya M, Nogueira TC et al. C/EBP homologous protein contributes to cytokine-induced pro-inflammatory responses and apoptosis in β-cells. Cell Death Differ 2012; 19: 1836-1846.
14. La Torre D. Immunobiology of beta-cell destruction. Adv Exp Med Biol 2012; 771: 194-218.
15. Saini P, Eyler DE, Green R, Dever TE. Hypusine-containing protein eIF5A promotes translation elongation. Nature 2009; 459: 118-121.
16. Sosenko JM, Skyler JS, Herold KC, Palmer JP. The metabolic progression to type 1 diabetes as indicated by serial oral glucose tolerance testing in the Diabetes Prevention Trial-type 1. Diabetes 2012; 61: 1331-1337.
17. Dias CAO, Gregio APB, Rossi D et al. eIF5A interacts functionally with eEF2. Amino Acids 2012; 42: 697-702.
18. Gregio APB, Cano VPS, Avaca JS, Valentini SR, Zanelli CF. eIF5A has a function in the elongation step of translation in yeast. Biochem Biophys Res Commun 2009; 380: 785-790.
19. Zhouravleva G, Frolova L, Le Goff X et al. Termination of translation in eukaryotes is governed by two interacting polypeptide chain release factors, eRF1 and eRF3. EMBO J 1995; 14: 4065-4072.
20. Eizirik DL, Sammeth M, Bouckenooghe T et al. The human pancreatic islet transcriptome: expression of candidate genes for type 1 diabetes and the impact of pro-inflammatory cytokines. PLoS Genet 2012; 8: e1002552.
21. Alkalaeva EZ, Pisarev AV, Frolova LY, Kisselev LL, Pestova TV. In vitro reconstitution of eukaryotic translation reveals cooperativity between release factors eRF1 and eRF3. Cell 2006; 125: 1125-1136.
22. Dever TE, Green R. The elongation, termination, and recycling phases of translation in eukaryotes. Cold Spring Harb Perspect Biol 2012; 4: a013706.
23. Harding HP, Ron D. Endoplasmic reticulum stress and the development of diabetes: a review. Diabetes 2002; 51: S455-S461.
24. Eizirik DL, Cardozo AK, Cnop M. The role for endoplasmic reticulum stress in diabetes mellitus. Endocr Rev 2008; 29: 42-61.
25. Cnop M, Ladriere L, Igoillo-Esteve M, Moura RF, Cunha DA. Causes and cures for endoplasmic reticulum stress in lipotoxic β-cell dysfunction. Diabetes Obes Metab 2010; 12: 76-82.
26. Engin F, Hotamisligil GS. Restoring endoplasmic reticulum function by chemical chaperones: an emerging therapeutic approach for metabolic diseases. Diabetes Obes Metab 2010; 12: 108-115.
27. Sonenberg N, Hinnebusch AG. Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell 2009; 136: 731-745.
28. Bygrave FL, Benedetti A. What is the concentration of calcium ions in the endoplasmic reticulum? Cell Calcium 1996; 19: 547-551.
29. Le Bacquer O, Petroulakis E, Paglialunga S et al. Elevated sensitivity to diet-induced obesity and insulin resistance in mice lacking 4E-BP1 and 4E-BP2. J Clin Invest 2007; 117: 387-396.
30. Matveyenko AV, Gurlo T, Daval M, Butler AE, Butler PC. Successful versus failed adaptation to high-fat diet-induced insulin resistance: the role of IAPP-induced beta-cell endoplasmic reticulum stress. Diabetes 2009; 58: 906-916.
31. Gwiazda KS, Yang TLB, Lin Y, Johnson JD. Effects of palmitate on ER and cytosolic Ca2+ homeostasis in beta-cells. Am J Physiol Endocrinol Metab 2009; 296: E690-E701.
32. Baldwin AC, Green CD, Olson LK, Moxley MA, Corbett JA. A role for aberrant protein palmitoylation in FFA-induced ER stress and β-cell death. Am J Physiol Endocrinol Metab 2012; 302: E1390-E1398.
33. Back SH, Kaufman RJ. Endoplasmic reticulum stress and type 2 diabetes. Annu Rev Biochem 2012; 81: 767-793.
34. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004; 18: 1926-1945.
35. Yoshida H, Matsui T, Yamamoto A, Okada T, Mori K. XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor. Cell 2001; 107: 881-891.
36. Yamaguchi S, Ishihara H, Yamada T et al. ATF4-mediated induction of 4E-BP1 contributes to pancreatic beta cell survival under endoplasmic reticulum stress. Cell Metab 2008; 7: 269-276.
37. Han D, Lerner AG, Vande Walle L et al. IRE1alpha kinase activation modes control alternate endoribonuclease outputs to determine divergent cell fates. Cell 2009; 138: 562-575.
38. Prostko CR, Brostrom MA, Malara EM, Brostrom CO. Phosphorylation of eukaryotic initiation factor (eIF) 2 alpha and inhibition of eIF-2B in GH3 pituitary cells by perturbants of early protein processing that induce GRP78. J Biol Chem 1992; 267: 16751-16754.
39. Kaufman RJ, Back SH, Song B, Han J, Hassler J. The unfolded protein response is required to maintain the integrity of the endoplasmic reticulum, prevent oxidative stress and preserve differentiation in β-cells. Diabetes Obes Metab 2010; 12: 99-107.
40. Wek RC, Jiang HY, Anthony TG. Coping with stress: eIF2 kinases and translational control. Biochem Soc Trans 2006; 34: 7-11.
41. Scheuner D, Song B, McEwen E et al. Translational control is required for the unfolded protein response and in vivo glucose homeostasis. Mol Cell 2001; 7: 1165-1176.
42. Scheuner D, Vander Mierde D, Song B et al. Control of mRNA translation preserves endoplasmic reticulum function in beta cells and maintains glucose homeostasis. Nat Med 2005; 11: 757-764.
43. Back SH, Scheuner D, Han J et al. Translation attenuation through eIF2alpha phosphorylation prevents oxidative stress and maintains the differentiated state in beta cells. Cell Metab 2009; 10: 13-26.
44. Harding HP, Zeng H, Zhang Y et al. Diabetes mellitus and exocrine pancreatic dysfunction in perk-/- mice reveals a role for translational control in secretory cell survival. Mol Cell 2001; 7: 1153-1163.
45. Zhang P, McGrath B, Li S et al. The PERK eukaryotic initiation factor 2 alpha kinase is required for the development of the skeletal system, postnatal growth, and the function and viability of the pancreas. Mol Cell Biol 2002; 22: 3864-3874.
46. Zhou D, Palam LR, Jiang L, Narasimhan J, Staschke KA, Wek RC. Phosphorylation of eIF2 directs ATF5 translational control in response to diverse stress conditions. J Biol Chem 2008; 283: 7064-7073.
47. Teske BF, Baird TD, Wek RC. Methods for analyzing eIF2 kinases and translational control in the unfolded protein response. Methods Enzymol 2011; 490: 333-356.
48. Sanz E, Yang L, Su T, Morris DR, McKnight GS, Amieux PS. Cell-type-specific isolation of ribosome-associated mRNA from complex tissues. Proc Natl Acad Sci USA 2009; 106: 13939-13944.
49. König J, Zarnack K, Luscombe NM, Ule J. Protein-RNA interactions: new genomic technologies and perspectives. Nat Rev Genet 2011; 13: 77-83.
50. Starck SR, Green HM, Alberola-Ila J, Roberts RW. A general approach to detect protein expression in vivo using fluorescent puromycin conjugates. Chem Biol 2004; 11: 999-1008.
51. Martinez SC, Tanabe K, Cras-Meneur C, Abumrad NA, Bernal-Mizrachi E, Permutt MA. Inhibition of Foxo1 protects pancreatic islet beta-cells against fatty acid and endoplasmic reticulum stress-induced apoptosis. Diabetes 2008; 57: 846-859.
52. Laybutt DR, Preston AM, Akerfeldt MC et al. Endoplasmic reticulum stress contributes to beta cell apoptosis in type 2 diabetes. Diabetologia 2007; 50: 752-763.
53. Huang CJ, Lin CY, Haataja L et al. High expression rates of human islet amyloid polypeptide induce endoplasmic reticulum stress mediated beta-cell apoptosis, a characteristic of humans with type 2 but not type 1 diabetes. Diabetes 2007; 56: 2016-2027.
54. Hartman MG, Lu D, Kim M-L et al. Role for activating transcription factor 3 in stress-induced beta-cell apoptosis. Mol Cell Biol 2004; 24: 5721-5732.
55. Marhfour I, Lopez XM, Lefkaditis D et al. Expression of endoplasmic reticulum stress markers in the islets of patients with type 1 diabetes. Diabetologia 2012; 55: 2417-2420.
56. Lebastchi J, Deng S, Lebastchi AH et al. Immune therapy and β-cell death in type 1 diabetes. Diabetes 2013; 62: 1676-1680.
57. Akirav EM, Lebastchi J, Galvan EM et al. Detection of beta cell death in diabetes using differentially methylated circulating DNA. Proc Natl Acad Sci USA 2011; 108: 19018-19023.
58. Husseiny MI, Kuroda A, Kaye AN, Nair I, Kandeel F, Ferreri K. Development of a quantitative methylation-specific polymerase chain reaction method for monitoring beta cell death in type 1 diabetes. PLoS One 2012; 7: e47942.
59. Steiner DF. On the discovery of precursor processing. Methods Mol Biol 2011; 768: 3-11.
60. Larsen CM, Faulenbach M, Vaag A et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007; 356: 1517-1526.
61. Larsen CM, Faulenbach M, Vaag A, Ehses JA, Donath MY, Mandrup-Poulsen T. Sustained effects of interleukin-1-receptor antagonist treatment in type 2 diabetes mellitus. Diabetes Care 2009; 32: 1663-1668.
62. Tersey SA, Nishiki Y, Templin AT et al. Islet β-cell endoplasmic reticulum stress precedes the onset of type 1 diabetes in the nonobese diabetic mouse model. Diabetes 2012; 61: 818-827.
63. Snorgaard O, Hartling SG, Binder C. Proinsulin and C-peptide at onset and during 12 months cyclosporin treatment of type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1990; 33: 36-42.
64. Scholin A, Nystrom L, Arnqvist H et al. Proinsulin/C-peptide ratio, glucagon and remission in new-onset Type 1 diabetes mellitus in young adults. Diabet Med 2011; 28: 156-161.
65. Snorgaard O, Kjems LL, Roder ME, Hartling SG, Dinesen B, Binder C. Proinsulin immunoreactivity in recent-onset IDDM: the significance of insulin antibodies and insulin autoantibodies. Diabetes Care 1996; 19: 146-150.
66. Ludvigsson J, Heding L. Abnormal proinsulin/C-peptide ratio in juvenile diabetes. Acta Diabetol Lat 1982; 19: 351-358.
67. Roder ME. Disproportionately elevated proinsulin levels precede the onset of insulin-dependent diabetes mellitus in siblings with low first phase insulin responses. The Childhood Diabetes in Finland Study Group. J Clin Endocrinol Metab 1994; 79: 1570-1575.
68. DeFronzo RA, Tripathy D, Schwenke DC et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 2011; 364: 1104-1115.
69. Xiang AH, Peters RK, Kjos SL et al. Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes 2006; 55: 517-522.
70. Gupta D, Kono T, Evans-Molina C. The role of peroxisome proliferator-activated receptor γ in pancreatic β cell function and survival: therapeutic implications for the treatment of type 2 diabetes mellitus. Diabetes Obes Metab 2010; 12: 1036-1047.
71. Akiyama M, Hatanaka M, Ohta Y et al. Increased insulin demand promotes while pioglitazone prevents pancreatic beta cell apoptosis in Wfs1 knockout mice. Diabetologia 2009; 52: 653-663.
72. Evans-Molina C, Robbins RD, Kono T et al. PPAR-{gamma} activation restores islet function in diabetic mice through reduction of ER stress and maintenance of euchromatin structure. Mol Cell Biol 2009; 29: 2053-2067.
73. Sachdeva MM, Claiborn KC, Khoo C et al. Pdx1 (MODY4) regulates pancreatic beta cell susceptibility to ER stress. Proc Natl Acad Sci USA 2009; 106: 19090-19095.
74. Kono T, Ahn G, Moss DR et al. PPAR-γ activation restores pancreatic islet SERCA2 levels and prevents β-cell dysfunction under conditions of hyperglycemic and cytokine stress. Mol Endocrinol 2012; 26: 257-271.
75. Yang Z, Zhou Z, Li X, Huang G, Lin J. Rosiglitazone preserves islet β-cell function of adult-onset latent autoimmune diabetes in 3 years follow-up study. Diabetes Res Clin Pract 2009; 83: 54-60.
76. Beales PE, Pozzilli P. Thiazolidinediones for the prevention of diabetes in the non-obese diabetic (NOD) mouse: implications for human type 1 diabetes. Diabetes Metab Res Rev 2002; 18: 114-117.
77. Augstein P, Augstein P, Dunger A et al. Prevention of autoimmune diabetes in NOD mice by troglitazone is associated with modulation of ICAM-1 expression on pancreatic islet cells and IFN-γ expression in splenic T cells. Biochem Biophys Res Commun 2003; 304: 378-384.
78. Drucker DJ. The biology of incretin hormones. Cell Metab 2006; 3: 153-165.
79. Yusta B, Yusta B, Baggio LL et al. GLP-1 receptor activation improves beta cell function and survival following induction of endoplasmic reticulum stress. Cell Metab 2006; 4: 391-406.
80. Shimoda M, Kanda Y, Hamamoto S et al. The human glucagon-like peptide-1 analogue liraglutide preserves pancreatic beta cells via regulation of cell kinetics and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes. Diabetologia 2011; 54: 1098-1108.
81. Cunha DA, Ladriere L, Ortis F et al. Glucagon-like peptide-1 agonists protect pancreatic β-cells from lipotoxic endoplasmic reticulum stress through upregulation of BiP and JunB. Diabetes 2009; 58: 2851-2862.
82. Shimizu S, Hosooka T, Matsuda T et al. DPP4 inhibitor vildagliptin preserves beta-cell mass through amelioration of endoplasmic reticulum stress in C/EBPB transgenic mice. J Mol Endocrinol 2012; 49: 125-135.
83. Liu Z, Christensson M, Forslöw A, De Meester I, Sundqvist K-G. A CD26-controlled cell surface cascade for regulation of T cell motility and chemokine signals. J Immunol 2009; 183: 3616-3624.
84. Reinhold D, Bank U, Bühling F et al. Inhibitors of dipeptidyl peptidase IV (DP IV, CD26) induces secretion of transforming growth factor-beta 1 (TGF-beta 1) in stimulated mouse splenocytes and thymocytes. Immunol Lett 1997; 58: 29-35.
85. Jelsing J, Vrang N, van Witteloostuijn SB, Mark M, Klein T. The DPP4 inhibitor linagliptin delays the onset of diabetes and preserves β-cell mass in non-obese diabetic mice. J Endocrinol 2012; 214: 381-387.
86. Cabrera SM, Colvin SC, Tersey SA, Maier B, Nadler JL, Mirmira RG. Effects of combination therapy with dipeptidyl peptidase-IV and histone deacetylase inhibitors in the NOD mouse model of type 1 diabetes. Clin Exp Immunol 2013; 172: 375-382.
87. Tian L, Gao J, Hao J et al. Reversal of new-onset diabetes through modulating inflammation and stimulating beta-cell replication in nonobese diabetic mice by a dipeptidyl peptidase IV inhibitor. Endocrinology 2010; 151: 3049-3060.
88. Varanasi A, Bellini N, Rawal D et al. Liraglutide as additional treatment for type 1 diabetes. Eur J Endocrinol 2011; 165: 77-84.
89. Kielgast U, Krarup T, Holst JJ, Madsbad S. Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual β-cell function. Diabetes Care 2011; 34: 1463-1468.
90. Ellis SL, Moser EG, Snell-Bergeon JK, Rodionova AS, Hazenfield RM, Garg SK. Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: a pilot, double-blind, randomized, crossover trial. Diabet Med 2011; 28: 1176-1181.
91. Garg SK, Moser EG, Bode BW et al. Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial. Endocr Pract 2012; 19: 19-28.
92. Ablamunits V, Henegariu O, Hansen JB et al. Synergistic reversal of type 1 diabetes in NOD mice with anti-CD3 and interleukin-1 blockade: evidence of improved immune regulation. Diabetes 2012; 61: 145-154.
93. Boerschmann H, Walter M, Achenbach P, Ziegler AG. Survey of recent clinical trials of the prevention and immunointervention of type 1 diabetes mellitus. Dtsch Med Wochenschr 2010; 135: 350-354.
94. Ozcan U, Yilmaz E, Ozcan L et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 2006; 313: 1137-1140.
95. Ozcan L, Ergin AS, Lu A et al. Endoplasmic reticulum stress plays a central role in development of leptin resistance. Cell Metab 2009; 9: 35-51.
96. Akerfeldt MC, Howes J, Chan JY et al. Cytokine-induced beta-cell death is independent of endoplasmic reticulum stress signaling. Diabetes 2008; 57: 3034-3044.
97. Tang C, Koulajian K, Schuiki I et al. Glucose-induced beta cell dysfunction in vivo in rats: link between oxidative stress and endoplasmic reticulum stress. Diabetologia 2012; 55: 1366-1379.
98. Xiao C, Giacca A, Lewis GF. Sodium phenylbutyrate, a drug with known capacity to reduce endoplasmic reticulum stress, partially alleviates lipid-induced insulin resistance and beta-cell dysfunction in humans. Diabetes 2011; 60: 918-924.
99. Mokhtari D, Welsh N. Potential utility of small tyrosine kinase inhibitors in the treatment of diabetes. Clin Sci 2010; 118: 241-247.
100. Oh JJ, Hong SK, Joo YM et al. Impact of sunitinib treatment on blood glucose levels in patients with metastatic renal cell carcinoma. Jpn J Clin Oncol 2012; 42: 314-317.
101. Templeton A, Brändle M, Cerny T, Gillessen S. Remission of diabetes while on sunitinib treatment for renal cell carcinoma. Ann Oncol 2008; 19: 824-825.
102. Han MS, Chung KW, Cheon HG et al. Imatinib mesylate reduces endoplasmic reticulum stress and induces remission of diabetes in db/db mice. Diabetes 2009; 58: 329-336.
103. Wang L, Perera BGK, Hari SB et al. Divergent allosteric control of the IRE1α endoribonuclease using kinase inhibitors. Nat Chem Biol 2012; 8: 982-989.